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Abstract
Background: Sodium restriction is recommended for patients with heart failure (HF) despite the lack 
of solid clinical evidence from randomized controlled trials. Whether or not sodium restrictions provide 
beneficial cardiac effects is not known.
Methods: The present study is a randomized, double-blind, controlled trial of stable HF patients with 
ejection fraction ≤ 40%. Patients were allocated to sodium restriction (2 g of sodium/day) vs. control 
(3 g of sodium/day). The primary outcome was change in N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) at 20 weeks. Secondary outcomes included quality of life and adverse safety events (HF 
readmission, blood pressure or electrolyte abnormalities).
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Results: Seventy patients were enrolled. Median baseline sodium consumption was 3268 (2225–4537) 
mg/day. Adherence to the intervention based on 24-hour urinary sodium was 32%. NT-proBNP and 
quality of life did not significantly change between groups (p > 0.05 for both). Adverse safety events 
were not significantly different between the arms (p > 0.6 for all). In the per protocol analysis, patients 
who achieved a sodium intake < 2500 mg/day at the  intervention conclusion showed improvements in  
NT-proBNP levels (between-group difference: –55%, 95% confidence interval –27 to –73%; p = 0.002) 
and quality of life (between-group difference: –11 ± 5 points; p = 0.04). Blood pressure decreased in 
patients with lower sodium intake (between-group difference: –9 ± 5 mmHg; p = 0.05) without signifi-
cant differences in symptomatic hypotension or other safety events (p > 0.3 for all).
Conclusions: Adherence assessed by 24-hour natriuresis and by the nutritionist was poor. The group 
allocated to sodium restriction did not show improvement in NT-proBNP. However, patients who 
achieved a sodium intake < 2500 mg/day appeared to have improvements in NT-proBNP and quality 
of life without any adverse safety signals. ClinicalTrials.gov Identifier: NCT03351283. (Cardiol J)
Key words: heart failure, sodium intake, NT-proBNP, quality of life
Introduction
Given the primacy of sodium in the patho-
physiology of heart failure (HF), it is intuitive 
that sodium restriction should be a primary goal 
of treatment [1–6]. However, despite being rec-
ommended by international guidelines, sodium 
restriction lacks solid clinical evidence from well-
powered randomized controlled trials [7, 8]. In fact, 
most of the evidence comes either from trials as-
sessing the effect of sodium restriction in non-HF 
populations such as patients with hypertension or 
from observational studies [9, 10]. Notably, avail-
able evidence has shown conflicting results making 
it difficult to support specific recommendations for 
sodium restriction in HF [11–19].
Traditionally, it would be expected that sodium 
restriction can lead to a negative sodium balance 
resulting in an improved volume status. However, 
severe sodium restriction might not be desirable 
because detrimental effects such as higher activa-
tion of the renin–angiotensin–aldosterone system 
and worse outcomes have been reported in clini-
cal trials as well as in a large observational study 
[17, 19]. Therefore, a gap in knowledge would be 
whether a non-severe sodium restriction could 
provide beneficial cardiac effects compared to 
a standard cardiac diet of ~3 g of sodium/day.
Thus, in the present randomized, controlled 
trial the effect of sodium restriction (2 g of so-
dium/day) was tested vs. a control group (3 g of 
sodium/day) in stable HF patients with reduced 
ejection fraction. Hypothesized herein, was that 
patients randomized to sodium restriction will 
show improved cardiac parameters such as B-type 




This was a randomized, double-blind, parallel-
-group trial in stable chronic HF patients with re-
duced ejection fraction. The study was registered in 
2017 (ClinicalTrials.gov Identifier: NCT03351283). 
Population
From January 2018 to November 2019, we 
assessed the eligibility of consecutive patients 
with chronic HF and reduced ejection fraction 
(≤ 40%) who attended our tertiary care center. 
Inclusion criteria were: 1) treatment with both an 
angiotensin-converting-enzyme inhibitors (ACEI) 
or angiotensin-receptor-blockers (ARB), and 
a beta-blocker; 2) stable medical treatment defined 
as no change in medications for the prior 4 weeks; 
3) age ≥ 18 years; 4) systolic blood pressure equal 
or greater than 90 mmHg; 5) highly motivated 
patients willing to participate. Excluded patients 
were those with: 1) a history of a HF admission in 
the prior month or with a New York Heart Asso-
ciation class III or IV; 2) an estimated glomerular 
filtration rate (eGFR) < 30 mL/min/1.73 m2 as-
sessed by the Chronic Kidney Disease Epidemiol-
ogy Collaboration (CKD-EPI) equation; 3) serum 
sodium < 130 mmol/L; 4) hemoglobin < 10 g/dL; 
5) patients scheduled to any intervention with 
the aim of improving their cardiovascular function 
(for example percutaneous coronary intervention, 
coronary artery bypass grafting, etc.); 6) valvular 
heart disease equal or greater than moderate de-
gree; 7) dementia; 8) cancer or any other condition 
compromising life expectancy within the following 
12 months. The study was approved by the Eth-
ics Committee of the documented hospital and all 
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participants provided written informed consent. 
The study was terminated when the target subject 
recruitment was achieved.
Intervention and adherence
Patients were randomized to either sodium 
restriction (goal of 2 g of sodium/day) vs. a control 
group (3 g of sodium/day). A 24-hour urinary col-
lection was collected the day before randomization 
to estimate baseline sodium intake. During the visit 
for randomization, a qualified nutritionist estimated 
dietary sodium intake using a standardized 24-hour 
food diary to obtain the dietary consumption of 
each patient. A thorough nutritional analysis of the 
subjects’ diets was obtained using the Food Proces-
sor® SQL Nutrition Analysis Software (version 7.9; 
ESHA Research). The nutritionist then calculated 
and provided multiple written diets (menus) each 
containing either 2 g (sodium restriction group) or 
3 g of sodium (control). For this study  the control 
group would be provided with menus of 3 g of 
sodium/day as this is the upper boundary recom-
mended by international guidelines [20]. During the 
initial visit, the nutritionist did a comprehensive 
explanation of each of the diets and educated the 
patients and their families with regards to hidden 
salt and the importance of following the provided 
diet. Diets were individually tailored to each patient 
to have appropriate macronutrients and calorie 
content. The nutritionist elaborated individualized 
menus following a comprehensive dietary approach 
so diets with either 2 or 3 g of sodium/day but had 
similar caloric and nutrient contents, which has been 
shown to be feasible [21]. Following randomization, 
patients were seen at 6 and 12 weeks where the 
nutritionist estimated dietary sodium intake with 
the food frequency questionnaire. Based on esti-
mated sodium intakes, the nutritionist went over 
the diets with the patient to improve adherence. 
At the end of the intervention (week 20), another 
24-hour urine collection was collected to estimate 
final sodium intake. The estimated sodium intakes 
from the 24-hour food dairy were used for advice, 
and the 24-hour urine collection was used to assess 
adherence. Completeness of 24-hour urine collec-
tions was determined on the basis of volume, with 
a threshold of ≥ 250 mL [22]. Adherence was defined 
as a urinary sodium excretion < 2500 mg in the 
sodium restriction group, and a sodium excretion 
between 2500 and 3500 mg/day in the control group.
Outcomes
The primary outcome was change in N-terminal 
pro-B-type natriuretic peptide (NT-proBNP) from 
baseline to the end of the 20-week intervention. 
Secondary outcomes were 1) change in quality of 
life quantified by the Minnesota Living with Heart 
Failure Questionnaire (MLHFQ), 2) change in 
eGFR, and 3) survival free of the composite of mor-
tality and hospitalization. Safety end points includ-
ed hyponatremia (serum sodium < 130 mmol/L), 
hyperkalemia (serum potassium > 5.5 mmol/L), 
hypotension (systolic blood pressure < 90 mmHg) 
and worsening renal function (defined as an abso-
lute increase in creatinine ≥ 0.3 mg/dL).
Sample size
Sample size was calculated with Stata SE 
version 16.0. Based on the study of Paterna et 
al. [11] mean ± standard deviation of BNP after 
180 days of a diet with ~2800 mg of sodium/day was 
555 ± 175 pg/mL vs. 745 ± 305 pg/mL with a diet 
of ~1800 mg sodium/day. For a significance level 
of alpha = 0.05, and a statistical power of 0.80, the 
minimum sample size was calculated as 29 patients 
per group. Assuming a 20% dropout rate the final 
sample size was estimated to be 70 patients.
Randomization
The www.randomization.com website was 
used to generate a simple sequential randomization 
plan. The nutritionist was responsible for the rand-
omization as he was the investigator who allocated 
participants to the intervention and followed them 
during the entire study. 
Blinding
Investigators involved in the assessment of 
outcomes as well as participants were blinded 
throughout the study. Participants received menus 
but they did not know if the menus aimed to have 
a sodium restriction with a goal of 2 g of sodium/ 
/day or 3 g of sodium/day. Baseline measurement of 
main variables (NT-proBNP, quality of life, eGFR, 
etc.) were assessed before randomization. 
Statistical methods
Continuous variables were presented as mean ± 
± standard deviation or median (quartile 1, quartile 3), 
according to the observed distribution. Baseline 
between-group differences were assessed with the 
Student t test or the Mann-Whitney test, as appro-
priate. Categorical variables were presented as ab-
solute or relative frequencies, and between-group 
differences were assessed with the Pearson c2 test. 
Changes from baseline to the end of the interven-
tion were assessed with the paired Student t test 
or the Wilcoxon signed-rank test. Endpoints were 
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estimated as changes from baseline to the end of the 
intervention and were compared with the Student 
t test or Mann-Whitney test. Survival-free of the com-
posite outcome was assessed with the log-rank test 
and the Kaplan-Meier method. Analyses were done 
by intention to treat with all available data. For the 
per protocol analysis, patients were divided into two 
groups based on 24-hour urinary sodium excretion 
at the end of the intervention: those who achieved 
< or ≥ 2500 mg of sodium/day. This cutoff value was 
chosen because this is the midpoint between 2000 
and 3000 mg, which were the targets of the inter-
vention. The goal of the per-protocol analyses was 
to describe if sodium restriction (2 g of sodium/day) 
could provide beneficial cardiac effects compared 
to patients who did not achieve sodium restriction. 
Specifically, it was not our intention to compare 
a specific 2-g sodium arm vs. a specific 3-g sodium 
arm but rather a sodium restriction group (2 g) 
vs. a group that did not achieve this restriction. 
Sensitivity analyses were done using 2750 or 3000 
mg of sodium/day as cutoff values, as well as with 
multivariable linear regression with each of the 
three cutoff values adjusting for age, sex, and 
changes in medications during the study (ACEI 
or ARB, and loop diuretics). For linear regression, 
skewed variables were log transformed to approxi-
mate normal distribution. P values < 0.05 were 
considered statistically significant. Stata SE version 




Ninety-nine patients were assessed for eligi-
bility, seventy of whom were randomized (Suppl. 
Fig. 1). Seven patients in the sodium restriction 
group and 6 patients in the control group refused 
to continue participating. Therefore, 57 (81%) 
patients completed the 20-week intervention. Two 
thirds were male and ischemic heart disease was 
the predominant etiology. Mean sodium consump-
tion at baseline (based on 24-hour sodium urinary 
excretion) was 3582 ± 1806 mg/day and was not 
significantly different between groups. Table 1 
summarizes baseline characteristics of randomized 
patients. Except for gender and use of aldosterone 
antagonist, the groups were comparable.
Adherence to intervention
At baseline, estimated sodium consumption 
was not statistically different between groups (so-
dium restriction group: 3305 ± 1989; control group: 
3911 ± 1533; p = 0.21). Based on 24-hour recalls 
at 6 and 12 weeks, estimated sodium consumption 
was not significantly different between groups 
(p > 0.10 for both). Sodium consumption at the 
end of the intervention (based on 24-hour urinary 
collection) showed a near significant association to 
be lower in the sodium restriction group (sodium 
restriction group: 3003 ± 1244 mg/day; control 
group: 3755 ± 1797 mg/day; mean difference 752, 
95% confidence interval [CI] 64 to 1568 mg/day, 
p = 0.07). However, the change in sodium intake 
was not significantly different between groups 
(sodium restriction group: –57 ± 1948 mg/day; 
control group: –426 ± 1571 mg/day; p = 0.50). 
Adherence to the intervention based on 24-hour 
urinary sodium was 32% and was similar between 
the 3-g compared to the 2-g group (28% vs. 35%, 
respectively; p = 0.55).
Outcomes. Intention-to-treat analysis 
In the overall population NT-proBNP did not 
significantly change from baseline to the end of 
the intervention (median change in NT-proBNP 
–29 pg/mL [interquartile range –267 to 211 pg/
mL], p = 0.69). No significant changes were 
observed between groups (p = 0.88) (Table 2, 
Fig. 1). Quality of life quantified by the MLHFQ 
improved from baseline to the end of the inter-
vention in the overall population (change –9.3 ± 
± 19.9, p < 0.001). A near significant associa-
tion was found to be an improvement in quality 
of life in the control group (p = 0.052) (Table 2, 
Fig. 1). No significant changes were observed for 
blood pressure, serum sodium, serum potassium, 
serum creatinine and weight between groups 
(p ≥ 0.14 for all). Fourteen patients experienced 
a HF readmission and 1 patient died. Out of the 
15 events, 8 occurred in the sodium restriction 
group and 7 in the control group. Survival free of 
HF readmission or death was not significantly dif-
ferent between groups (p = 0.89). The proportion 
of hyponatremia, hyperkalemia, hypotension, and 
worsening renal function was also similar between 
groups (Table 3). 
Per-protocol analysis
Based on 24-hour urinary sodium excretion, 
36% of patients achieved a sodium intake < 2500 
mg/day at the end of the intervention. In the group 
with < 2500 mg/day, sodium intake statistically 
changed from baseline to the end of the interven-
tion: mean change –1076 mg (95% CI –354 to –1798, 
p = 0.006), while in the group with ≥ 2500 mg/day, 
the change was not statistically significant: mean 
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change +263 (95% CI –437 to +963, p = 0.45). 
The between groups difference was statistically 
different: 1339 mg (95% CI 2398 to 280 mg/day); 
p = 0.01 (Fig. 2). NT-proBNP levels (p = 0.01) 
and quality of life (p = 0.04) improved in the group 
with < 2500 mg/day compared to the group with 
≥ 2500 mg/day (Fig. 2, Table 4). Likewise, blood 
pressure decreased in the patients with lower 
sodium consumption compared to the other group 
(p = 0.05). No significant changes were observed 
for serum sodium, potassium, creatinine and 
weight between groups (p > 0.10 for all) (Fig. 2, 
Table 4). The proportion of hyponatremia, hyper-
kalemia, hypotension, and worsening renal function 
was similar between groups (Table 3). In sensitivity 
analysis, similar results were observed for 
NT-proBNP levels and quality of life in favor of the 
group with lower sodium intake when using cutoff 
values of 2750 or 3000 mg, and after adjusting for 
covariables with the three different cutoff values 
(Suppl. Table 1). 
Discussion
There are scarce data from randomized trials 
to support an appropriate level of sodium restric-
tion in patients with HF. The current main findings 
are: 1) A nutritional intervention aimed to reduce 
sodium intake did not reduce NT-proBNP levels; 
however, 2) Patients who achieved < 2500 mg of 
Table 1. Baseline characteristics of patients.
Total population  
(n = 70)






Age [years] 60 ± 12 61 ± 12 58 ± 13 0.32
Male 47 (67%) 20 (54%) 27 (82%) 0.014
Past medical history
Diabetes 26 (37%) 14 (38%) 12 (36%) 0.90
Hypertension 34 (49%) 19 (51%) 15 (45%) 0.62
Dyslipidemia 36 (51%) 17 (46%) 19 (58%) 0.33
Ischemic heart disease 51 (73%) 23 (62%) 28 (85%) 0.058
LVEF [%] 30 ± 7 29 ± 8 32 ± 7 0.11
Physical exam and functional class
Systolic blood pressure [mmHg] 111 ± 15 110 ± 16 112 ± 15 0.64
Body mass index [kg/m2] 28.1 ± 4.7 27.3 ± 4.6 29.0 ± 4.8 0.12
NYHA class I 31 (44%) 16 (43%) 15 (45%) 0.85
NYHA class II 39 (56%) 21 (57%) 18 (55%) 0.85
MLHFQ (points) 38 (19, 58) 35 (12, 54) 40 (27, 59) 0.15
Laboratory data
Serum sodium [mmol/L] 141 ± 4 141 ± 3 142 ± 4 0.51
eGFR [mL/min/1.73 m2] 64 ± 25 67 ± 25 62 ± 24 0.37
NT-proBNP [pg/mL] 762 (363, 2683) 1402 (378, 3387) 540 (350, 1704) 0.14
Urinary sodium excretion [mg/day] 3268 (2225, 4537) 3259 (1645, 4209) 3419 (2990, 4605) 0.12
Medication
Loop diuretic dose (mg of furosemide 
equivalent/day)
20 (0, 40) 40 (0, 40) 20 (0, 40) 0.64
Loop diuretics 50 (70%) 27 (73%) 23 (70%) 0.76
ACEI, ARB or ARNI 66 (94%) 35 (95%) 31 (94%) > 0.99
Beta-blocker 63 (90%) 34 (92%) 29 (88%) 0.70
Aldosterone antagonist 51 (73%) 31 (84%) 20 (61%) 0.029
Continuous data is shown as mean ± standard deviation, or median (quartile 1, quartile 3). ACEI — angiotensin converting enzyme inhibitor; 
ARB — angiotensin receptor blocker; ARNI — angiotensin receptor neprilysin inhibitor; eGFR — estimated glomerular filtration rate; LVEF — 
left ventricular ejection fraction; MLHFQ — Minnesota Living with Heart Failure Questionnaire; NT-proBNP — N-terminal pro-B-type natriuretic 
peptide; NYHA — New York Heart Association
6 www.cardiologyjournal.org









































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Intention to treat analysis. Bars show the mean 
change in parameter. Error bars show standard error of 
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sodium/day showed improvements in NT-proBNP 
levels and quality of life; 3) Sodium intake within 
the limits of the present study appeared to be safe 
as very few safety issues were noted; 4) Even in 
highly motivated patients with a tight follow-up, ad-
herence to sodium restriction was remarkably low.
In the Geriatric Out-of-Hospital Randomized 
Meal Trial in Heart Failure (GOURMET) and 
Prevent Adverse Outcomes in Heart Failure 
by Limiting Sodium Pilot Study (PROHIBIT), 
4 weeks and 12 weeks of interventions aimed at 
reducing sodium intake, respectively, were not 
Table 3. Safety parameters.






P < 2500 mg 
sodium/ 
/day (n)




Serum sodium < 130 mmol/L 0 0 — 0 0 —
Serum potassium > 5.5 mmol/L 1 0 > 0.99 1 0 0.35
Systolic blood pressure < 90 mmHg 2 2 > 0.99 1 2 > 0.99
Worsening renal function (> 0.3 mg/dL) 3 1 0.62 2 2 0.61
Figure 2. Per protocol analysis. Bars show mean change in parameter. Error bars show standard error of the mean; 



















































< 2500 mg < 2500 mg
< 2500 mg < 2500 mg
≥ 2500 mg ≥ 2500 mg






Quality of life Systolic blood pressure
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associated with reductions in BNPs [23, 24]. Con-
versely, in the Study of Dietary Intervention Under 
100 MMOL in Heart Failure (SODIUM-HF), 
sodium restriction for 6 months did result in 
a significant reduction of BNP levels [25]. In the 
present study, a 20-week intervention did not show 
improvements in NT-proBNP levels, likely due to 
poor adherence. However, patients who achieved 
a sodium intake < 2500 mg/day did show improve-
ment in NT-proBNP levels. Importantly, length 
of interventions was notably different among the 
4 mentioned studies. Shorter interventions (2 weeks 
in GOURMET and 12 weeks in PROHIBIT) were 
not associated with improvements in NT-proBNP 
levels. Conversely, longer interventions (6 months 
in the SODIUM-HF and 20 weeks in the per-
protocol analysis of the present study) did show 
a potential benefit. Therefore, one might hypothe-
size that the effect of sodium restriction on natriu-
retic peptides may be possible in the long-term.
Regarding quality of life, a statistically signifi-
cant improvement was observed in the group that 
achieved < 2500 mg of sodium/day compared to 
that of the control group. This finding is consistent 
with the GOURMET, PROHIBIT, and SODIUM-HF 
studies, in which interventions aimed to reduce 
sodium intake showed improvement in quality of 
life despite somehow different interventions: food 
was provided in the first two, and written menus 
in the last one [23–25]. Therefore, it is likely that 
sodium restriction could have improved quality 
of life, and these beneficial effects may appear as 
soon as 4 weeks in the GOURMET study and may 
continue for up to 6 months (SODIUM-HF and the 
present study). 
Importantly, neither in the present study nor 
in the other 3 randomized trials an increased risk 
of adverse outcomes was observed in patients allo-
cated to sodium restriction [23–25]. These findings 
contrast with the study performed by Italian inves-
tigators where patients with intensive restriction 
compared to moderate sodium restriction (1800 mg 
vs. 2800 mg of sodium/day, respectively) showed 
higher risk of hospital readmission [11]. Notably, in 
that study patients were treated with higher doses 
of loop diuretics (250 mg to 500 mg of furosemide 
per day) compared to the present study (~20 mg of 
furosemide per day) or the PROHIBIT trial (~50 mg 
of furosemide equivalents per day). Given that loop 
diuretics strongly enhance neurohormonal activa-
tion [26, 27], and lower sodium chloride intake 
also stimulates the renin–angiotensin–aldosterone 
system [28, 29], it is possible that these differ-
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remarkable difference is that in the present study, 
the GOURMET, and PROHIBIT trials most pa-
tients were taking ACEI/ARBs, while in the Italian 
study only 30% were taking captopril. The effect 
of sodium restriction in patients with or without 
ACEI/ARB was reported in the HART study 
(A Self-management Intervention for Mild to Mod-
erate Heart Failure) where worse outcomes with 
sodium restriction were observed only in patients 
who were not receiving ACEI/ARB [19].
Another remarkable observation in the present 
study is that it is very hard for patients with HF to 
adhere to diet interventions that aim to decrease 
sodium intake. This finding is consistent with 
a previous trial where very few patients achieved 
a sodium consumption < 2000 mg/day even with 
dietitian education, or even in the PROHIBIT 
study where adherence was ~50% despite having 
food provided [24, 30]. The SODIUM-HF trial will 
provide unique information to understand if diet 
interventions aiming to decrease sodium intake 
can improve clinical outcomes [31].
With regards to medication, it was noted that 
70% of the population were receiving loop diuret-
ics which has been shown to potentially affect the 
accuracy of 24-hour urine collections likely because 
in stable HF patients loop diuretics are key to main-
taining sodium homeostasis as demonstrated in 
a recent study where loop diuretic omission re-
sulted in a 50% reduction in natriuresis [32, 33]. 
Importantly, in the present study the use of aldos-
terone antagonists was higher in the sodium re-
striction group at baseline, and although all patients 
were taking ≤ 25 mg of spironolactone, which is 
not typically considered a natriuretic dose, some 
potential natriuretic or cardiac effect of these drugs 
cannot be negated and thus a possible influence on 
the observed results. Interestingly, serum sodium 
actually increased in the sodium restriction group; 
however, the magnitude of the change was not 
clinically relevant (1 mmol/L during the 20-week 
intervention) and the between-group difference did 
not reach statistical significance (p = 0.08). 
Limitations of the study
This was a single-center study with a relative-
ly small sample size; thus, results should be inter-
preted cautiously. Namely, the present study might 
be underpowered to detect a smaller difference 
of change in NT-proBNP levels. Baseline sodium 
intake was not excessively high; therefore, results 
may not be extrapolated to patients with higher 
sodium intake. Assessments of sodium intake 
4 times during a 20-week period and do not con-
sider whether there were large fluctuations be-
tween these times. Adherence was assessed 
by 24-hour urinary collections, which may not 
be a reproducible method, and completeness 
of urine collections was determined on volume 
alone, which may be an insensitive method [34]. 
In addition, adherence to the intervention was 
poor. Food was not provided but patients were 
asked to follow written diets, which decreases 
adherence to the intervention. However, in the 
rigorously conducted PROHIBIT study diet 
compliance was ~50% in support of the notion 
that diet interventions are extremely challeng-
ing [24]. NT-proBNP showed a near statistical 
association to be lower in the control group at 
baseline, and thus some impact  cannot be ruled 
out on the results because the primary outcome 
was a change in NT-proBNP. Finally, there were 
more men in the control group which could have 
potentially affected adherence to the interven-
tion and consequently the observed results.
Conclusions
Adherence to an intervention aimed to reduce 
sodium intake was poorly assessed both with the 
24-hour urinary sodium excretion and by the nutri-
tionist; thus, this study shows the challenges of this 
type of intervention and suggests its limited useful-
ness in future studies. No significant improvement 
in NT-proBNP levels were observed in patients 
allocated to an intervention aiming to reduce 
sodium intake. However, patients who achieved 
a sodium intake < 2500 mg/day at the end of the 
20-week intervention did show improvements in 
NT-proBNP levels and quality of life without any 
adverse safety signal. 
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